Bladder cancers respond to EGFR inhibitors.
Researchers have discovered that nearly 25% of muscle-invasive bladder cancers fall into a "basal-like" subgroup that overexpresses EGFR and other proteins in the same pathway. EGFR inhibitors like erlotinib and cetuximab are effective against basal-like cell lines and tumors implanted into mice, arguing for clinical trials of the drugs for patients with this cancer subtype.